Asparaginase use for the treatment of acute lymphoblastic leukemia

[1]  Amy P Abernethy,et al.  Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). , 2015, JAMA oncology.

[2]  N. Boissel,et al.  Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on Asparaginase , 2015, Journal of adolescent and young adult oncology.

[3]  L. Dupuis,et al.  Allergic Reactions Associated with Intravenous Versus Intramuscular Pegaspargase: A Retrospective Chart Review , 2015, Pediatric Drugs.

[4]  B. Asselin,et al.  Asparaginase pharmacokinetics and implications of therapeutic drug monitoring , 2015, Leukemia & lymphoma.

[5]  D. Neuberg,et al.  Polymorphisms of Asparaginase Pathway and Asparaginase-Related Complications in Children with Acute Lymphoblastic Leukemia , 2014, Clinical Cancer Research.

[6]  C. McCracken,et al.  Comparison of Allergic Reactions to Intravenous and Intramuscular Pegaspargase in Children with Acute Lymphoblastic Leukemia , 2014, Pediatric hematology and oncology.

[7]  K. Schmiegelow,et al.  Asparaginase‐associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol , 2014, British journal of haematology.

[8]  M. Schrappe,et al.  Optimizing asparaginase therapy for acute lymphoblastic leukemia , 2013, Current opinion in oncology.

[9]  B. Bostrom,et al.  Comparison of allergic reactions to pegasparaginase given intravenously versus intramuscularly , 2012, Pediatric blood & cancer.

[10]  A. Bleyer,et al.  Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel , 2011, Leukemia & lymphoma.

[11]  H. Çaksen,et al.  A Desensitization Protocol in Children With L-Asparaginase Hypersensitivity , 2010, Journal of pediatric hematology/oncology.

[12]  V. Poggi,et al.  Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution , 2010, Leukemia & lymphoma.

[13]  T. Jaing,et al.  Hyperammonemic encephalopathy after induction chemotherapy for acute lymphoblastic leukemia. , 2009, Journal of pediatric hematology/oncology.

[14]  S. Sallan,et al.  Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase‐associated pancreatitis , 2009, Pediatric blood & cancer.

[15]  R. Pieters,et al.  Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial. , 2008, Blood.

[16]  M. Bernard,et al.  Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study , 2008, Haematologica.

[17]  N. Heerema,et al.  Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. , 2008, Blood.

[18]  D. Flockhart,et al.  Predicting asparaginase‐associated pancreatitis , 2007, Pediatric blood & cancer.

[19]  J. Shuster,et al.  Intensified PEG-L-asparaginase and Antimetabolite-based Therapy for Treatment of Higher Risk Precursor-B Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group , 2007, Journal of pediatric hematology/oncology.

[20]  A. Castelnuovo,et al.  Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta‐analysis , 2007, Journal of thrombosis and haemostasis : JTH.

[21]  L. Iacoviello,et al.  Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. , 2006, Blood.

[22]  V. Sawlani,et al.  L-Asparaginase-Induced Reversible Posterior Leukoencephalopathy Syndrome in a Child with Acute Lymphoblastic Leukemia , 2002, Pediatric Neurosurgery.

[23]  S. Suciu,et al.  Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. , 2002, Blood.

[24]  J. Neglia,et al.  A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. , 2002, Blood.

[25]  K. Schmiegelow,et al.  Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system , 2001, British journal of haematology.

[26]  M. Schrappe,et al.  Pegylated asparaginase (OncasparTM) in children with ALL: drug monitoring in reinduction according to the ALL/NHL‐BFM 95 protocols , 2000, British journal of haematology.

[27]  M. Relling,et al.  Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  C. Schiffer,et al.  Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia , 1998, Leukemia.

[29]  D. Coppola,et al.  Comparative pharmacokinetic studies of three asparaginase preparations. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  G. Bodey,et al.  Effect of L-asparaginase on carbohydrate metabolism. , 1970, Metabolism: clinical and experimental.